Correlation between non-alcoholic fatty liver disease (NAFLD) and dyslipidemia in type 2 diabetes

Diabetes & Metabolic Syndrome
Saini Krishan

Abstract

Non-alcoholic fatty liver means the presence of hepatosteatosis without significant alcohol consumption; it is strongly associated with obesity and metabolic disorder like type 2 diabetes and dyslipideamia. NASH may progress to advanced stages of hepatic fibrosis and cirrhosis. Increased body mass index and viral genotype contribute to steatosis in chronic hepatitis. The sonographic features of NAFLD include the presence of bright hepatic echotexture deep attenuation, and vascular blurring either singly or in combination. Dyslipidemia in patients with NAFLD is atherogenic in nature and it is characterized by increased levels of serum triglycerides and decreased levels of HDL cholesterol. Statins are potent lipid-lowering agents which decrease LDL cholesterol by 20-60%, decrease triglycerides by 10-33% and increase HDL cholesterol by 5-10% for the patients with NAFLD.

References

Nov 1, 1991·Journal of Gastroenterology and Hepatology·J R FiataroneG C Farrell
Nov 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·I R Wanless, J S Lentz
Jan 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·E E PowellL W Powell
Dec 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M R TeliC P Day
Mar 30, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·L F HouriganE E Powell
May 14, 1999·The Journal of Clinical Endocrinology and Metabolism·P MarceauJ G Kral
May 29, 1999·Gastroenterology·C A MatteoniA J McCullough
Jun 2, 2000·Gastroenterology·V RatziuT Poynard
Feb 5, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Gianfranco PaganoMario Rizzetto
Feb 5, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Giulio Marchesini, Gabriele Forlani
Mar 27, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Zobair M YounossiJanus P Ong
Dec 31, 2002·JAMA : the Journal of the American Medical Association·Ali H MokdadJames S Marks
Jan 16, 2003·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Elizabeth M BruntAdrian M Di Bisceglie
Jan 25, 2003·Journal of Gastroenterology and Hepatology·Geoffrey C Farrell
Apr 30, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Brent A Neuschwander-Tetri, Stephen H Caldwell
Aug 16, 2006·Alimentary Pharmacology & Therapeutics·E N LiberopoulosD P Mikhailidis

❮ Previous
Next ❯

Citations

Dec 7, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Xinting WangJie Yang
Jan 31, 2020·Frontiers in Immunology·Lívia Pimentel de Sant'AnaKelly Grace Magalhães
May 20, 2021·Journal of Sports Medicine·Timothy A RengersElise C Brown
Jun 30, 2021·Inflammopharmacology·Ojus SardanaOnkar Bedi
Aug 17, 2021·Food Science and Biotechnology·Tae Wook KimUy Dong Sohn

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.